The San Antonio Community Clinical Oncology Program (SACCOP) is a consortium, involving Santa Rosa Hospital and the Baptist Memorial Hospital System in San Antonio, Texas. These two institutions with 1354 beds are pooling their oncology patient base of 2000 new cases per year, 52% of which are diagnosed in minority groups (44% Hispanics, 8% Blacks), to establish the first COOP in Texas with the specific purpose of: a. increasing minority patient participation in cancer treatment research, b. introducing into the Hispanic community concepts of cancer research as a non-threatening approach to treatment of neoplastic diseases, c. involving primary care physicians in the overall cancer program by providing education in state-of-the-art therapies, d. establishing a network of primary care physicians who will be instrumental in implementing cancer control activities, e. generating a data base on Hispanic patients from which future cancer treatment and cancer control interventions appropriate for this segment of the U.S. population can be developed. The SACCOP will be a tight organization with centralized data management and defined committee structure. Ninety percent of research subjects will originate from within Bexar County. It is expected at least 50% of these will be of Mexican-American heritage. The majority of the cohesive group of investigators and the participating nursing staffs are fluent in Spanish. Furthermore, a Social Service Committee is being built into the operational plan to address specific minority related issues. Affiliations are in place with SWOG for treatment protocols and with M.D. Anderson for cancer control activities.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Cooperative Clinical Research--Cooperative Agreements (U10)
Project #
5U10CA052757-03
Application #
2094964
Study Section
Special Emphasis Panel (SRC (42))
Project Start
1990-09-21
Project End
1993-05-31
Budget Start
1992-06-15
Budget End
1993-05-31
Support Year
3
Fiscal Year
1992
Total Cost
Indirect Cost
Name
Santa Rosa Health Care Corporation
Department
Type
DUNS #
City
San Antonio
State
TX
Country
United States
Zip Code
78207
Chu, David Z J; Hussey, Michael A; Alberts, David S et al. (2011) Colorectal Chemoprevention Pilot Study (SWOG-9041), randomized and placebo controlled: the importance of multiple luminal lesions. Clin Colorectal Cancer 10:310-6
Blanke, Charles D; Chansky, Kari; Christman, Kathy L et al. (2010) S9511: a Southwest Oncology Group phase II study of trimetrexate, 5-fluorouracil, and leucovorin in unresectable or metastatic adenocarcinoma of the stomach. Am J Clin Oncol 33:117-20
Albain, Kathy S; Barlow, William E; Shak, Steven et al. (2010) Prognostic and predictive value of the 21-gene recurrence score assay in postmenopausal women with node-positive, oestrogen-receptor-positive breast cancer on chemotherapy: a retrospective analysis of a randomised trial. Lancet Oncol 11:55-65
Albain, Kathy S; Barlow, William E; Ravdin, Peter M et al. (2009) Adjuvant chemotherapy and timing of tamoxifen in postmenopausal patients with endocrine-responsive, node-positive breast cancer: a phase 3, open-label, randomised controlled trial. Lancet 374:2055-63
Kuptsova, Nataliya; Kopecky, Kenneth J; Godwin, John et al. (2007) Polymorphisms in DNA repair genes and therapeutic outcomes of AML patients from SWOG clinical trials. Blood 109:3936-44
Smalley, Stephen R; Benedetti, Jacqueline K; Williamson, Stephen K et al. (2006) Phase III trial of fluorouracil-based chemotherapy regimens plus radiotherapy in postoperative adjuvant rectal cancer: GI INT 0144. J Clin Oncol 24:3542-7
Hutchins, Laura F; Green, Stephanie J; Ravdin, Peter M et al. (2005) Randomized, controlled trial of cyclophosphamide, methotrexate, and fluorouracil versus cyclophosphamide, doxorubicin, and fluorouracil with and without tamoxifen for high-risk, node-negative breast cancer: treatment results of Intergroup Protocol INT-010 J Clin Oncol 23:8313-21